12:19:56 EDT Tue 15 Jun 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Z:ABBV - ABBVIE INC - http://www.abbvie.com12:19:56 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABBV - Z0.1115.23·115.240.6115.235-0.165-0.11,093.2125,69016,379115.38  115.48  114.52118.28  79.110112:03:02Jun 1215 min RT 2¢

Recent Trades - Last 10 of 16379
Time ETExPriceChangeVolume
12:03:12Z115.22-0.18100
12:03:09Z115.22-0.184
12:03:05Z115.215-0.185100
12:03:05Z115.215-0.1851
12:03:05Z115.215-0.18526
12:03:04Z115.21-0.192
12:03:03Z115.23-0.1799
12:03:03Z115.23-0.171
12:03:03Z115.23-0.171
12:03:03Z115.22-0.18150

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-06-12 07:02U:ABBVNews ReleaseIMBRUVICA ® (ibrutinib) Plus VENCLEXTA ®/VENCLYXTO ® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
2021-06-11 01:03U:ABBVNews ReleaseNew Data Shows AbbVie's VENCLYXTO ®/VENCLEXTA ® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
2021-06-08 08:45U:ABBVNews ReleaseAllergan Aesthetics and BOTOX ® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign
2021-06-07 11:30U:ABBVNews ReleaseCAPTIVATE Study Shows an IMBRUVICA ® (ibrutinib) Plus VENCLEXTA ®/VENCLYXTO ® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
2021-06-04 09:00U:ABBVNews ReleaseResults from IMBRUVICA ® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
2021-06-02 08:30U:ABBVNews ReleaseAbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-06-02 08:00U:ABBVNews ReleasePhase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI ®) Achieved Endoscopic Response and Clinical Remission at One Year
2021-06-02 07:30U:ABBVNews ReleaseAbbVie to Present Analysis Evaluating Continuous RINVOQ ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
2021-06-02 07:00U:ABBVNews ReleaseNew Long-Term Efficacy and Safety Analyses Evaluating RINVOQ ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress
2021-05-26 08:15U:ABBVNews ReleaseAbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference
2021-05-26 08:00U:ABBVNews ReleaseAbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting
2021-05-25 08:00U:ABBVNews ReleaseAbbVie Receives European Commission Approval of VENCLYXTO ® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
2021-05-25 08:00U:ABBVNews ReleaseAbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
2021-05-24 09:15U:ABBVNews ReleaseAbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI ®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
2021-05-24 08:45U:ABBVNews ReleaseThe Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ ® (upadacitinib) in Atopic Dermatitis